These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6135918)

  • 1. New treatment for prostatic cancer.
    Lancet; 1983 Aug; 2(8347):438. PubMed ID: 6135918
    [No Abstract]   [Full Text] [Related]  

  • 2. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 3. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of cancer of the prostate. Role of gonadorelin analogs].
    Steg A
    Presse Med; 1989 May; 18(20):1007-9. PubMed ID: 2524792
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Kerle D; Williams G; Ware H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
    Allen JM; Kerle DJ; Ware H; Doble A; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1766. PubMed ID: 6315133
    [No Abstract]   [Full Text] [Related]  

  • 8. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer.
    Waxman J; Man A; Hendry WF; Whitfield HN; Besser GM; Tiptaft RC; Paris AM; Oliver RT
    Br Med J (Clin Res Ed); 1985 Nov; 291(6506):1387-8. PubMed ID: 2933122
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hormone therapy of male genital cancer (prostatic cancer)].
    Machida T; Ikemoto I
    Gan To Kagaku Ryoho; 1987 Oct; 14(10):2845-52. PubMed ID: 2444164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Luteinizing hormone-releasing hormone agonists for treatment of breast cancer].
    Gez E; Kovner F
    Harefuah; 1990 Jun; 118(11):655-8. PubMed ID: 2143745
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma--a multi-centre clinical study.
    Kaisary AV; Ryan PG; Turkes A; Peeling WB; Griffiths K
    Prog Clin Biol Res; 1988; 260():89-100. PubMed ID: 2966408
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with an LHRH analogue in patients with advanced pancreatic cancer. A preliminary report.
    Andrén-Sandberg A
    Acta Chir Scand; 1990 Aug; 156(8):549-51. PubMed ID: 2146849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of LH_RH analogs in the treatment of cancer of the prostate. A report of the conference organized by ICI_Pharma Laboratories (part 1)].
    Prog Urol; 1991 Feb; 1(1):165-8. PubMed ID: 1364642
    [No Abstract]   [Full Text] [Related]  

  • 15. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparative study of a long acting luteinizing hormone releasing hormone agonist (Decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Preliminary report.
    De Sy WA; de Meyer JM; Casselman J; De Smet R; Renders G; Schelfhout W; De Wilde P
    Acta Urol Belg; 1986; 54(2):221-9. PubMed ID: 2942015
    [No Abstract]   [Full Text] [Related]  

  • 17. [Histrelin acetate--the first once yearly LHRH agonist].
    Altarac S
    Lijec Vjesn; 2011; 133(9-10):320-2. PubMed ID: 22165080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 19. [The use of agonist analogues of luteinizing hormone--releasing hormone in the treatment of prostatic carcinoma].
    Gez E; Ben-Yosef R; Libson E; Biran S
    Harefuah; 1987 Mar; 112(5):239-41. PubMed ID: 3301586
    [No Abstract]   [Full Text] [Related]  

  • 20. Gonadotrophin releasing hormone analogues for advanced prostate cancer.
    Drug Ther Bull; 1992 Aug; 30(17):65-7. PubMed ID: 1396111
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.